EXTINA® Foam is a well-tolerated treatment for seb derm.

• EXTINA® Foam is safe for use in patients 12 years of age or older1

• In clinical trials, EXTINA® Foam was well tolerated1


Adverse Reactions Reported by >1% Subjects in Clinical Trials1

Important safety information

EXTINA® (ketoconazole) Foam, 2% is indicated for the topical treatment of seborrheic dermatitis in immunocompetent patients 12 years of age and older. Safety and efficacy of EXTINA® Foam for treatment of fungal infections have not been established.

The most common adverse reactions to EXTINA® Foam observed in clinical trials
(incidence >1%) were application site burning (10%) and application site reaction (6%).

EXTINA® Foam may result in contact sensitization, including photoallergenicity.

EXTINA® Foam is not for ophthalmic, oral, or intravaginal use.

Full Prescribing Information for EXTINA® Foam

Extina<sup>®</sup> - The difference is in the delivery

Download the patient brochure Prescribing Info